NDAINJECTIONINJECTABLE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
MYCAMINE (micafungin sodium) by Bayer is [see microbiology (12. First approved in 2005.
Drug data last refreshed 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYCAMINE (micafungin sodium) is an intravenous echinocandin antifungal agent used to treat invasive candidiasis, candidemia, and esophageal candidiasis. It works by inhibiting fungal cell wall synthesis through inhibition of 1,3-beta-D-glucan synthase. The drug is indicated across adult and pediatric populations (4 months and older) with dose-proportional pharmacokinetics.
$0.249MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending ($249K in 2023), indicating consolidation of brand team resources and shift toward generic/lifecycle extension strategies.
Mechanism of Action
[see Microbiology (12.4)] . 12.2 Pharmacodynamics The pharmacodynamics of micafungin related to hematogenous Candida meningoencephalitis are described in other sections of the prescribing information [see Use in Specific Populations (8.4) and Microbiology (12.4)] . 12.3 Pharmacokinetics Adults The…
Worked on MYCAMINE at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.